Ascendis, Visen' once-weekly growth hormone drug beats daily hGH in Chinese patients in trial

Nov. 17, 2022 5:01 AM ETAscendis Pharma A/S (ASND)By: Ravikash, SA News Editor

Growth Hormone concept

hafakot/iStock via Getty Images

Ascendis Pharma (ASND) and Visen Pharmaceuticals reported detailed results from a phase 3 trial of their once-weekly lonapegsomatropin (TransCon hGH), showing it was better at increasing height than daily human growth hormone (hGH) in children with growth hormone deficiency (GHD) in

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.